Key result
Finerenone does not increase arrhythmias, high-grade AV block, or cardiac arrest risk versus control.
Why the study?
The safety profile of finerenone regarding arrhythmic outcomes in patients with chronic kidney disease and type 2 diabetes mellitus remains uncertain.
Does finerenone increase the risk of arrhythmias or conduction disorders in patients with chronic kidney disease and type 2 diabetes mellitus?
Meta-Analysis (n=21,015)
Does finerenone increase the risk of arrhythmias or conduction disorders in patients with chronic kidney disease and type 2 diabetes mellitus?
Finerenone does not appear to increase the risk of clinically reported arrhythmic events or conduction disorders in patients with chronic kidney disease and type 2 diabetes mellitus.
Answers are grounded in this paper and cite their sources.
Supports finerenone use in CKD with T2DM without arrhythmia concerns; reinforces safety alongside established CV and renal benefits.
BACKGROUND Finerenone reduces kidney and cardiovascular events in patients with chronic kidney disease and type 2 diabetes mellitus, but its safety profile in terms of arrhythmic outcomes remains uncertain. METHODS We systematically searched PubMed, Cochrane Library, and ClinicalTrials.gov (inception-March 2026) for randomized trials reporting arrhythmias or conduction disorders with finerenone versus control. Risk ratios (RRs) were pooled using fixed-effects models; heterogeneity was assessed with I2. RESULTS Six trials (21,015 patients; mean age 67.2 years; 33.9% women) were included. Finerenone was not associated with increased atrial or ventricular arrhythmias, high-grade atrioventricular block, or cardiac arrest (all RRs non-significant; low heterogeneity). CONCLUSIONS Finerenone shows no clear increase in clinically reported arrhythmic events in the pooled analysis; however, the included studies were not designed to assess the rate of arrhythmic outcomes and might have underestimated the true rates.
No takes yet. Share an insight, caveat, or question.
Bazoukis et al. (2026) conducted a meta-analysis in chronic kidney disease and type 2 diabetes mellitus (n=21,015). Finerenone vs. control was evaluated on arrhythmias or conduction disorders (p=non-significant). Finerenone was not associated with increased atrial or ventricular arrhythmias, high-grade atrioventricular block, or cardiac arrest compared to control.
Synapse has enriched 10 related papers. Consider them for comparative context: